Animal and 'in vitro' experiences learned that hCG (human Chorionic Gonadotropin) is capable to protect from breast cancer. Receptors for hCG/LH (luteinizing hormone) are present on human female and male breast cancer cells. hCG decreases proliferation and invasion of breast cancer MCF-7 cells by inhibiting NFkappa B, AP-1 activation and other genes. Doxorubicin toxicity is enhanced by conjugation with beta-hCG in MCF-7 cells. All these pieces of evidence suggest that hCG is active in human breast cancer. Direct proof however is missing. We performed a pilot study phase I trial for testing the inhibitory effects or recombinant hCG (rhCG) on primary breast cancer. 25 postmenopausal women with newly diagnosed breast cancers of more than 1,5 cm were biopsied before randomization to receive either 500 µg rhCG (n=20) or placebo. After 2 weeks, surgery was done and tissues were analysed with regard to morphological, immunohistochemical and biochemical changes in tissues and plasma. rhCG reduces significantly the proliferative index and the expression of both the oestrogen receptor and progesterone receptor. rhCG does not modify the hormonal level of estradiol, progesterone, inhibin and follicle stimulating hormone but increases significantly the level of LH. In a second pilot study we tested the clinical efficacy through an openlabel single centre study in 13 postmenopausal women with metastatic breast cancer. 500 µg rhCG once every two days shows activity in postmenopausal metastatic breast cancer. The time to progression is relatively short. Response to previous hormonal treatment is indicative for rhCG activity. Given the data in primary and 2 Page 2 of 18 A c c e p t e d M a n u s c r i p t metastatic breast cancer rhCG further large scale investigation is highly warranted. rhCG can be an realistic option in (chemo-) prevention trials.
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Introduction
Breast cancer is the most common malignancy of women in the Western world, affecting approximately 1 in 9. In spite of advances in screening, diagnosis and treatment, approximately one fifth of affected women will die of their disease 1 
Among the epidemiological factors identified to reduce breast cancer risk is pregnancy, particularly pregnancy at an early reproductive age. Both direct and indirect mechanisms have been postulated for this effect, and of the role of human Chorionic Gonadotropin (hCG) 8 . Further work has identified the hCG receptor in normal human breast tissue and more recently in breast cancer tissue. Human Chorionic Gonadotropin has also demonstrated an antiproliferative effect on breast cancer cells in vitro. This inhibitory effect has been shown to be independent of ovarian function. Based on this evidence, and on the pre-clinical and human safety information generated on this well-characterized hormone, studies were designed on efficacy and safety to evaluate the potential benefit of recombinant-hCG in patients with metastasized breast cancer.
Human chorionic gonadotropin is produced by placental trophoblasts as early as 6 days post-conception and stimulates both corpus luteum and early feto-placental endocrine functions. To maintain early pregnancy, hCG stimulates secretion of estrogen and progesterone by the corpus luteum organ until this function is assumed by the placenta itself 9 . Evidence suggests 15 that 72 per cent of the human breast cancers contain a combined hCG/LH receptor on the cell membrane 16 . The presence of the receptor is correlated with premenopausal status, well differentiated tumors, the presence of ERalpha receptors and the lobular adenocarcinoma subtype. It is presumed that the A c c e p t e d M a n u s c r i p t presence of hCG/LH receptors predict for hCG activity i.e. inhibition of tumor growth as is the case in vitro situations 17 . Also the progression of preneoplastic lesion such as intraductal proliferations and carcinoma in situ has been noted 18 , 19 . However, despite the awareness of this useful knowledge, we are not able to analyse the receptors at the time of the study.
The potential benefit of hCG in treatment of breast cancer comes from the demonstration of a direct effect of hCG in the mammary epithelium in vitro using MCF-10 and MCF-7 cells, a normal and a neoplastic human breast epithelial cell line, respectively 20 , 21 . In these cells, hCG inhibits growth, depresses cell proliferation, lengthens the G1 phase of the cell cycle, and induces the synthesis of alpha and beta inhibin, non-steroidal glycoproteins belonging to the TGF-beta family with demonstrated tumor suppressor activity. There is also evidence that LH/hCG receptors are expressed in these cell lines 22 , 23 .
Due its molecular similarity to hLH and its ready availability by extraction from urine, hCG has been used pharmacologically for use in men, women and children. In men, hCG induces testosterone production; in women, hCG induces final follicular maturation and triggers ovulation in patients receiving infertility therapy; an in male children, hCG induces descent of the cryptorchid testis. Currently, hCG of recombinant origin is at the scene to replace the pharmaceutical product extracted from urine.
Human CG administered to virgin rats induces maturation of the breast, formation of lobules and milk secretion, mimicking the effect of pregnancy 24 , 25 . The differentiated gland has a lower proliferative activity and a more efficient mechanism of DNA repair, Thirteen patients accepted to enter the study. They received 500 µg rhCG IM every other day for at least 60 days. Then tumor response was evaluated. The evaluation was repeated every 60 days. 4 patients had progressive disease after 60 days, 7 patients had stable disease and 2 patients had a decrease of the soft tissue localizations for more than 50 per cent of the initial diameters. No complete remission was seen partly as a result of the high percentage of patients with bone lesions. The longest remission was 240 days in a patient with partial remission.
The response in the liver was evaluable in 9 patients: with 2 progressive disease, 2 partial remissions and 5 stable diseases. The longest remission was seen in a partial regression patient and lasted more than 240 days. The response in the bone could be evaluated in 7 patients with 2 progressive diseases and 5 stable diseases. The longest stable disease was 240 days.
Overall the response to rhCG treatments was correlated to the response on previous hormonal therapy. Patients with earlier progressive disease on hormonal treatment (n=2) one had a progressive disease on rhCG. 7 patients with stable disease on previous hormonal treatment showed SD on rhCG and 2 progressive diseased. Of two patients with prior partial remission on hormonal treatment, one has partial remission on rhCG.
Conclusion
In conclusion, rhCG is active in the treatment of postmenopausal metastatic breast cancer. The response duration is relatively short but most of the patients had
